2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Brolucizumab 6mg: new trials by email Literature Review of Brolucizumab 6mg trials Research Report on Brolucizumab 6mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration Brolucizumab 6mg, Aflibercept 2 mg - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 397 | 2019-11-29 | 2024-12-09 |
Eye Diseases (1) · Macular Degeneration (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Diseases (1) · Scotoma (1) · Vascular Diseases (1) · Vision Disorders (1) · Wet Macular Degeneration (1)
China (1) · South Korea (1)